Compounds for the treatment of female sexual dysfunction
First Claim
Patent Images
1. A method for treating female sexual arousal disorder comprising the step of orally delivering to a female suffering from female sexual arousal disorder an agent in an amount to cause potentiation of cAMP in the sexual genitalia of the female;
- wherein the agent is optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient, and the agent a phosphodiesterase 2 inhibitor.
2 Assignments
0 Petitions
Accused Products
Abstract
A method of treating a female suffering from FSD, in particular FSAD, is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia; wherein the agent is in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient.
-
Citations
24 Claims
-
1. A method for treating female sexual arousal disorder comprising the step of orally delivering to a female suffering from female sexual arousal disorder an agent in an amount to cause potentiation of cAMP in the sexual genitalia of the female;
- wherein the agent is optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient, and the agent a phosphodiesterase 2 inhibitor.
- View Dependent Claims (2, 3, 4, 5)
-
6. A method for treating female sexual arousal disorder comprising the step of orally delivering to a female suffering from female sexual arousal disorder a phosphodiesterase 2 inhibitor in an amount to cause potentiation of cAMP in the sexual genitalia of said female;
- wherein said phosphodiesterase 2 inhibitor is admixed with a pharmaceutically acceptable carrier, diluent or excipient.
- View Dependent Claims (7, 8, 9, 10)
-
11. A method for treating a female sexual arousal disorder comprising the step of potentiating in vivo cAMP in female sexual genitalia with an orally administered phosphodiesterase inhibitor, wherein said phosphodiesterase inhibitor directly potentiates cAMP according to an assay method comprising the step of determining whether said phosphodiesterase 2 inhibitor directly potentiates cAMP;
- wherein a potentiation of cAMP in the presence of said inhibitor is indicative that said inhibitor is useful in the treatment of said female sexual arousal disorder.
- 12. A method for treating female sexual arousal disorder in a female suffering from female sexual arousal disorder comprising the step of orally delivering to a female suffering from female sexual arousal disorder a therapeutically effective amount of a phosphodiesterase 2 inhibitor, wherein said phosphodiesterase 2 inhibitor is optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.
Specification